Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
MALVERN, Pa., Oct. 25, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its third quarter financial results before the market opens on Thursday, November 3, 2016.
Management will conduct a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 97609147 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania and more information can be found by visiting the company’s website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
